Century Therapeutics, Inc. (NASDAQ:IPSC) reported weaker-than-expected second-quarter results.
Century Therapeutics posted quarterly loss of 56 cents per share, missing analysts’ expectations for a loss of 54 cents per share. The company’s sales came in $99,000, missing estimates of $1.14 million.
Century Therapeutics shares fell 1.7% to close at $2.85 on Wednesday.
These analysts made changes to their price targets on Century Therapeutics following earnings announcement.
- Chardan Capital cut the price target on Century Therapeutics from $19 to $17. Chardan Capital analyst Geulah Livshits maintained a Buy rating.
- HC Wainwright & Co. lowered the price target on Century Therapeutics from $17 to $13. HC Wainwright & Co. analyst Mitchell Kapoor maintained a Buy rating on the stock.
- EF Hutton analyst Tony Butler, meanwhile, reiterated Century Therapeutics with a Buy and maintained a $16 price target.
Read This Next: Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday
